Edition:
United States

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

1.79USD
23 Apr 2018
Change (% chg)

$-0.08 (-4.28%)
Prev Close
$1.87
Open
$1.86
Day's High
$1.93
Day's Low
$1.75
Volume
17,579
Avg. Vol
47,160
52-wk High
$7.30
52-wk Low
$1.53

Chart for

About

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize,... (more)
No analyst recommendations are available for .

Overall

Beta: 2.73
Market Cap(Mil.): $21.20
Shares Outstanding(Mil.): 11.34
Dividend: --
Yield (%): --

Financials

  BPTH.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.79 -- --
ROI: -73.11 -0.74 13.19
ROE: -98.87 -2.80 15.00

BRIEF-Bio-Path Holdings Reports Full Year 2017 Financial Results

* PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULTS Source text for Eikon: Further company coverage:

Apr 03 2018

BRIEF-Bio Path Holdings Says Board Increased Its Size From Four Members To Five Members

* BIO PATH HOLDINGS INC SAYS ON FEB 1, 2018, BOARD OF CO, INCREASED ITS SIZE FROM FOUR MEMBERS TO FIVE MEMBERS - SEC FILING Source text: [http://bit.ly/2GQ9Xup] Further company coverage:

Feb 05 2018

BRIEF-Bio Path Holdings Provides Clinical Update And 2018 Business Outlook

* BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2018 BUSINESS OUTLOOK

Dec 29 2017

BRIEF-Bio-Path Holdings Q3 loss per share $0.02

* Bio-Path Holdings reports third quarter 2017 financial results

Nov 09 2017

BRIEF-Bio-Path Holdings announces $4 mln registered direct offering

* Bio-Path Holdings, Inc. Announces $4 million registered direct offering

Nov 03 2017

Competitors

Earnings vs. Estimates